ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 696 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis

    Chenyang Lu1,2, Beth Wallace3,4,5, Wenyi Fu2,6 and Yi Liu1, 1Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, 2Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 3VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, 4Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, 5Institute for Healthcare Policy and Innovation, Michigan Medicine, Ann Arbor, MI, 6Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China, Shenyang, China

    Background/Purpose: Many targeted synthetic DMARD (tsDMARD) and biological DMARD (bDMARD) were recently approved for treatment of active psoriatic arthritis (PsA), but their comparative efficacy and…
  • Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting

    Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit

    Clara Pérez-Velásquez1, Maria Luz Garcia Vivar2, Silvia Perez Barrio3, Eva Galindez-Agirregoikoa1, Esther Ruíz Lucea1, Ignacio Torre-Salaberri4, Olaia Fernández-Berrizbeitia1, Ana Rosa Inchaurbe Pellejero2, Juan Blanco Madrigal1, Edurne Guerrero Basterretxea2, Itziar Calvo Zorrilla2, Oihane Ibarguengoitia2, David Montero2, Natalia Rivera-García1, Maria Jesus Allande Lopez Linares1 and Iñigo Gorostiza-Hormaetxe5, 1Rheumatology, University Hospital of Basurto, Bilbao, Spain, 2Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, 3Dermatology, University Hospital of Basurto, Bilbao, Spain, 4Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 5Unit of Research, University Hospital of Basurto, Bilbao, Spain

    Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…
  • Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting

    Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

    Michael D. George1, Joshua Baker2 and Alexis Ogdie3, 1Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
  • Abstract Number: 699 • 2018 ACR/ARHP Annual Meeting

    New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease

    Silvia Tamanini1, Micaela Fredi2, Chiara Bazzani1, Maria Grazia Lazzaroni3, Melissa Fernandes4, Cecilia Nalli3, Angela Tincani3 and Franco Franceschini2, 1Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, 2Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, 3Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 4Autoimmune Unit/Internal Medicine Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (C.H.L.C), Lisbona, Portugal

    Background/Purpose: Vedolizumab (VDZ) is a monoclonal antibody approved for inflammatory bowel disease, with a gut-specific mechanism of action, binding to α4β7 integrine expressed on gut-homing…
  • Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting

    Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial

    Guro Løvik Goll1, Nils Bolstad2, Ines Iria3,4, Rolf Klaasen5, Kristin Kaasen Jørgensen6, Inge C Olsen7, Ana Valido8, Maria J Saavedra9, João E. Fonseca10, Merete Lorentzen11, Cato Mork12, Knut EA Lundin13, David J Warren14, Espen A. Haavardsholm15, Jorgen Jahnsen16, Tore Kvien15 and João Gonçalves17, 1Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 3Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, 4iMed- Research Institute for medicines, Lisbon, Portugal, 5Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 6Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 7Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 9Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, 10Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 11Dept of Dermatology, Rikshospitalet, Oslo, Norway, 12Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 13Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, 14Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 15Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 16Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 17Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

    Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
  • Abstract Number: 701 • 2018 ACR/ARHP Annual Meeting

    Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment

    Vibeke Strand1, M. Elaine Husni2, Jenny Griffith3, Yan Song4, Rakesh Singh5, Jing Zhao6 and Keith A. Betts7, 1Stanford University, Palo Alto, CA, 2Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 3AbbVie, Inc., North Chicago, IL, 4Analysis Group, Inc., Boston, MA, 5AbbVie Inc., North Chicago, IL, 6Analysis Group Inc, Boston, MA, 7Analysis Group, Inc., Los Angeles, CA

    Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…
  • Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting

    Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Dongze Wu1, Priscilla Wong1, James F Griffith2, Jiang Yue1 and Lai-Shan Tam3, 1Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 2Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, 3Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…
  • Abstract Number: 703 • 2018 ACR/ARHP Annual Meeting

    Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab

    Anastasia Dupré1, Michael Collins2, Franck Carbonnel3, Xavier Mariette4,5 and Raphaele Seror1, 1Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, 2Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-Enterology, Université Paris Sud, Le Kremlin Bicêtre, France, 3Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-enterology, Université Paris Sud, Le Kremlin Bicêtre, France, 4Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, 5Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France

    Background/Purpose: Vedolizumab is a humanised IgG1 monoclonal antibody anti-α4β7 integrin agent used in inflammatory bowel disease (IBD). It modulates gut inflammation by preventing leukocyte migration…
  • Abstract Number: 704 • 2018 ACR/ARHP Annual Meeting

    Metabolomics Analysis of Insulin Resistance in Mild/Inactive Non-Diabetic Systemic Lupus Erythematosus Women

    Claudia Mendoza Pinto1, Mario García-Carrasco2, Gerardo Díaz-Merino3, Pamela Soto-Santillan4, Rossy Mejia-Ocampo5, Pamela Munguía-Realpozo3 and Alejandro Ruiz-Arguelles5, 1Systemic Autoimmune Diseases Research Unit,, UMAE, HE CMN Manuel Ávila Camacho-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, 3Systemic Autoimmune Diseases Research Unit,, Hospital de Especialidades UMAE CMN, Instituto Mexicano del Seguro Social, Puebla, Mexico, 4Systemic Autoimmune Diseases Research Unit, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, 5Laboratorios Clínicos de Puebla, Puebla, Mexico

    Background/Purpose: SLE patients present a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than age- and sex-matched healthy controls. Advances in technology are…
  • Abstract Number: 705 • 2018 ACR/ARHP Annual Meeting

    Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    Claudia Mendoza Pinto1,2, Nicolás Molano-González3, Adriana Rojas-Villarraga4, Verónica Vallejo-Ruiz5, Socorro Méndez-Martínez6 and Mario García-Carrasco1,7, 1Systemic Autoimmune Diseases Research Unit,, UMAE, HE CMN Manuel Ávila Camacho-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico, 2Departament of Research, Facultad de Medicina, Benemerita Universidad Autonoma de Puebla, Puebla, Mexico, 3Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia, 4Instituto de Investigaciones de la Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia, 5Virology Laboratory, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico, 6Research in Health Coordination,, Delegation of Puebla, Instituto Mexicano del Seguro Social, Puebla, Mexico, 7Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico

    Background/Purpose: Human papillomavirus (HPV), a common sexually-transmitted infection, is considered a necessary cause of cervical cancer. The objectives of this systematic review and meta-regression were:…
  • Abstract Number: 706 • 2018 ACR/ARHP Annual Meeting

    Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study

    Jocelyn S. Gandelman1, Omair A. Khan2, Megan Shuey3, Jacquelyn E. Neal2, Alyson Dickson4, April Barnado5, Li Wang2, William Dupont2, C. Michael Stein4 and Cecilia P. Chung4, 1Vanderbilt University School of Medicine, Nashville, TN, 2Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 3Department of Pharmacology, Vanderbilt University, Nashville, TN, 4Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 5Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose:  Resistant hypertension (RHTN) is associated with increased risk of cardiovascular events in the general population. Patients with systemic lupus erythematous (SLE) have increased cardiovascular…
  • Abstract Number: 707 • 2018 ACR/ARHP Annual Meeting

    Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus

    Monica Vazquez-Del Mercado1,2, Felipe Perez-Vazquez3, Eduardo Gomez-Bañuelos1, Efrain Chavarria-Avila3, Arcelia Llamas-Garcia4, Karla I. Arrona-Rios4, Gustavo I Diaz-Rubio3, Sergio Duran-Barragan4, Rosa E Navarro-Hernandez3, Bethel Jordan-Estrada3, Natalia Prado-Bachega5, Miguel A. A. Gonzalez-Beltran3, Carlos G Ramos-Becerra6, Fernando Grover-Paez6, David Cardona-Muller7 and Ernesto German Cardona-Muñoz7, 1Servicio de Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, 2Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Mexico, 3Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, 4Servicio en Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, 5Anesthesiology, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, 6Centro Universitario de Ciencias de la Salud, INTEC, Universidad de Guadalajara, Guadalajara, Mexico, 7Departamento de Fisiología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico

    Background/Purpose: It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic…
  • Abstract Number: 708 • 2018 ACR/ARHP Annual Meeting

    The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE

    Nicolas Paez-Venegas1, Bethel Jordan-Estrada2, Efrain Chavarria-Avila2, Felipe Perez-Vazquez2, Eduardo Gomez-Bañuelos3, Rafael Medina-Davalos1, Jose A. Ontiveros-Gonzalez4, Gustavo I Diaz-Rubio2, Rosa E Navarro-Hernandez2 and Monica Vazquez-Del Mercado3, 1Instituto Jalisciense de Salud Mental, ZAPOPAN, Mexico, 2Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, 3Servicio de Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, 4Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico

    Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, chronic and multisystemic disease, which can be related with a long range of neuropsychiatric manifestations, including cognitive…
  • Abstract Number: 709 • 2018 ACR/ARHP Annual Meeting

    Differential Characteristics of Lupus Psychosis and Steroid Psychosis

    Shunsei Hirohata1,2,3, Yoshinori Kanai4, Akiko Mitsuo5, Yoshiaki Tokano4 and Hiroshi Hashimoto4, 1Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 2Nobuhira Hospital, Tatsuno, Japan, 3Kitasato University School of Medicine, Sagamihara, Japan, 4Juntendo University School of Medicine, Tokyo, Japan, 5Rheumatology, National Hospital Organization Disaster Medical Center, Tokyo, Japan

    Background/Purpose: Psychiatric manifestations are relatively common in patients with systemic lupus erythematosus (SLE).  Since there are a number of factors causing psychiatric manifestations other than…
  • Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting

    An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival

    Basile Tessier-Cloutier1, David Twa2, Eva Baecklund3, Randy Gascoyne4, Nathalie A. Johnson5, Carin Backlin3, Diane L. Kamen6, Ann E. Clarke7, Rosalind Ramsey-Goldman8, Jennifer LF Lee9, Pedro Farinha4 and Sasha Bernatsky10, 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, 2Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 4Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, 5Department of Oncology, McGill University, Montreal, QC, Canada, 6Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 8FSM, Northwestern University, Chicago, IL, 9Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 10Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…
  • « Previous Page
  • 1
  • …
  • 1049
  • 1050
  • 1051
  • 1052
  • 1053
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology